TG Therapeutics TGTX EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from TG Therapeutics’s reported figures.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's EBITDA?
- TG Therapeutics (TGTX) reported EBITDA of $34.83M in Q1 2026.
- How has TG Therapeutics's EBITDA changed year-over-year?
- TG Therapeutics's EBITDA increased by 303.6% year-over-year, from $8.63M to $34.83M.
- What is the long-term trend for TG Therapeutics's EBITDA?
- Over 3 years (2021 to 2025), TG Therapeutics's EBITDA has grown at a -29.0% compound annual growth rate (CAGR), from -$344.49M to $123.38M.
- What does EBITDA mean?
- Operating cash profit before interest, taxes, and non-cash charges.
- How do you interpret EBITDA?
- Higher is better and widely used to value capital-intensive businesses, but it ignores the real cost of capex — pair it with free cash flow. (Defined as EBIT + D&A so EBITDA = EBIT + D&A holds exactly.)
- How does EBITDA compare across companies?
- Standard cross-company operating-profit proxy for non-financials; not meaningful for banks and insurers.